HAEMATO AG is a publicly traded pharmaceutical company focusing on the growth markets of high-end specialty pharmaceuticals in the indication areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house development of innovative medical devices for the beauty market was started. HAEMATO AG assumes that first products will hit the market in the coming year, which has already created the basis for further growth and additional income.